Skip to main content

Advertisement

Table 2 Medication at baseline in the four categories of body composition classified using A/G ratio

From: Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study

  Normal (n = 187) Sarcopenia (n = 171) Obesity (n = 275) Sarcopenic obesity (n = 83) p value*
Insulin (%) 34 39 36 39 0.756
Sulfonylureas (%) 20 21 24 21 0.652
Metformins (%) 24 15 43 29 < 0.001
Alpha-GIs (%) 16 16 10 12 0.146
Glinides (%) 5 4 3 5 0.704
TZDs (%) 9 3 8 5 0.068
DPP4 inhibitors (%) 27 30 39 46 0.005
SGLT2 inhibitors (%) 1 0 1 1 0.631
GLP1-RAs (%) 2 2 4 1 0.581
ACEIs (%) 5 2 3 5 0.396
ARBs (%) 41 32 56 50 < 0.001
CCBs (%) 32 28 46 43 < 0.001
Alpha blockers (%) 1 1 3 0 0.122
Beta blockers (%) 11 8 11 18 0.129
Diuretics (%) 10 10 8 12 0.790
Statins (%) 47 31 54 40 < 0.001
Fibrates (%) 5 2 2 2 0.103
Ezetimib (%) 5 2 2 0 0.082
EPAs (%) 3 2 3 5 0.774
UA lowering agents (%) 8 8 15 13 0.029
Anti-platelet agents (%) 18 22 26 33 0.050
  1. ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers, CCBs, calcium channel blockers; DPP4, dipeptidyl peptidase 4; EPA, eicosapentaenoic acid; GIs, glycosidase inhibitors; GLP1-RA, glucagon-like peptide-1 receptors agonist; SGLT2, sodium-glucose cotransporter 2; TZDs, thiazolidinediones; UA, uric acid
  2. * Chi square test or Fisher’s exact test